{
  "id": 18192075,
  "title": "Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites",
  "url": "https://urgent.news/2026/11/04/lonza-expanding-u-s-cdmo-footprint-with-purchase-of-five-merck-kgaa",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-04T21:34:47.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/lonza-expanding-u-s-cdmo-footprint-with-purchase-of-five-merck-kgaa-sites/"
  },
  "original_language": "en",
  "account": "Lonza is set to expand its U.S. contract development and manufacturing organization (CDMO) presence by purchasing five sites from Merck KGaA. The deal is valued at around CHF 100 million to CHF 500 million, equivalent to $121.6 million to $608.2 million. Upon completion, Lonza's U.S. CDMO network will increase from four to nine sites, boosting the company's workforce by nearly 25% with an additional 1,100 employees. This expansion will result in a combined headcount of over 6,000 workers. The acquisition of these sites will provide end-to-end development and manufacturing capabilities in the U.S., focusing on areas such as antibody-drug conjugates, viral vectors for cell and gene therapies, advanced drug-delivery technologies, and commercial-scale spray-drying. Lonza's CEO, Wolfgang Wienand, stated that the acquisition aligns with the company's \"One Lonza\" strategy and aims to enhance the company's resilience and global manufacturing network. Merck KGaA's Chairman of the Executive Board and Group CEO, Kai Beckmann, described the transaction as an important step in advancing his company's mid- to long-term strategic agenda. The transaction is expected to strengthen Merck's Life Science sector by focusing investments on scientific leadership and positioning Lonza as a strong partner for customers during the innovation to launch and commercial supply stages.",
  "summary": "The deal would expand Lonza’s U.S. CDMO network from four to nine sites and grow the company’s U.S. workforce nearly 25% by adding approximately 1,100 employees, resulting in a combined headcount of more than 6,000 employees. The post Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Merck KGaA to exit CDMO business, divesting US sites to Lonza",
        "url": "https://urgent.news/2026/11/03/merck-kgaa-to-exit-cdmo-business-divesting-us-sites-to-lonza",
        "published": "2026-11-03T09:54:12.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}